Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.
The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Aicha Diba
Investor Relations
Direct : +31 20 240 6100
Main: +31 20 566 7394
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
